1
|
Hsu CW, Peterson CW, Eberhart CG, Meyer CF, Armstrong DK, Fiallos K, Campbell AA. Ocular adnexal sebaceous carcinoma in a patient with Li-Fraumeni syndrome. Orbit 2024:1-5. [PMID: 39072610 DOI: 10.1080/01676830.2024.2382268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2024] [Accepted: 07/14/2024] [Indexed: 07/30/2024]
Abstract
Li-Fraumeni syndrome (LFS) is caused by a pathogenic germline variant at the TP53 locus and is associated with an increased predisposition to a variety of cancers. The neoplasms most frequently associated with LFS are sarcomas, breast cancer, brain tumors, and adrenocortical carcinomas. In this case report, we present a 43-year-old male diagnosed with an ocular adnexal sebaceous carcinoma of the right upper eyelid who was confirmed to have LFS with subsequent genetic testing. The mutational profile of both the patient's genetic screen and tumor sequencing were congruent, demonstrating the same pathogenic loss-of-function TP53 variant. This case report highlights the importance of pursuing genetic testing in patients with a history of multiple tumor types, particularly those with uncommon diagnoses. In this case, confirmation of LFS had important implications for personalized patient care, including identification of contraindicated treatment interventions and the imaging modalities necessary for vigilant follow-up screening.
Collapse
Affiliation(s)
- Chia W Hsu
- Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Cornelia W Peterson
- Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- Department of Comparative Pathobiology, Tufts University Cummings School of Veterinary Medicine, North Grafton, Massachusetts, USA
| | - Charles G Eberhart
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Christian F Meyer
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Deborah K Armstrong
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Katie Fiallos
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Ashley A Campbell
- Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| |
Collapse
|
2
|
Vass A, Polgár N, Sándor SA, Ágoston D, Rózsa P, Csányi I, Ócsai H, Baltás E, Oláh J, Kis EG, Tóth-Molnár E. The role of electrochemotherapy in the treatment of locally advanced or recurrent eyelid-periocular basal cell carcinoma: long-term results. Int J Dermatol 2024. [PMID: 38924059 DOI: 10.1111/ijd.17346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2024] [Revised: 06/08/2024] [Accepted: 06/11/2024] [Indexed: 06/28/2024]
Abstract
BACKGROUND While electrochemotherapy (ECT) is increasingly utilized as a highly effective method in the treatment of tumors in the head and neck region, there is significantly less data available for eyelid-periocular skin tumors. Our group reported the first extensive case series of eyelid-periocular basal cell carcinoma (BCC) patients with short-term follow-up treatment with ECT. The present study aims to report our long-term results of eyelid-periocular BCC cases treated with ECT. METHODS The treatments were performed according to the ESOPE (European Standard Operating Procedures on Electrochemotherapy) guidelines using the Cliniporator™ device. All patients received bleomycin-based ECT, administered intratumorally or intravenously. Tumor response was evaluated using the RECIST 1.1 criteria. RESULTS The results of 19 patients treated with ECT are presented. Four patients had locally advanced primary tumors, while 15 patients had recurrent tumors. Bleomycin was administered intratumorally in four patients and intravenously in 15 patients. The overall response was 100%, while the complete response rate proved to be 95%. In three cases (15.8%), recurrence was observed during the mean follow-up period of 78.9 months. CONCLUSIONS ECT can effectively treat locally advanced or recurrent BCC in the eyelid-periocular skin region. Excellent tumor control can be achieved with good functional and cosmetic results without systemic adverse events with long interval follow-up.
Collapse
Affiliation(s)
- Attila Vass
- Department of Ophthalmology, University of Szeged, Szeged, Hungary
| | - Nóra Polgár
- Department of Ophthalmology, University of Szeged, Szeged, Hungary
| | | | - Dóra Ágoston
- Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary
| | - Petra Rózsa
- Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary
| | - Ildikó Csányi
- Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary
| | - Henriette Ócsai
- Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary
| | - Eszter Baltás
- Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary
| | - Judit Oláh
- Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary
- Department of Oncotherapy, University of Szeged, Szeged, Hungary
| | - Erika Gabriella Kis
- Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary
| | - Edit Tóth-Molnár
- Department of Ophthalmology, University of Szeged, Szeged, Hungary
- Faculty of Health Sciences and Social Studies, University of Szeged, Szeged, Hungary
| |
Collapse
|
3
|
Mukarram M, Khachemoune A. Upper and Lower Eyelid Malignancies: Differences in Clinical Presentation, Metastasis, and Treatment. Arch Dermatol Res 2024; 316:429. [PMID: 38907769 DOI: 10.1007/s00403-024-03163-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2024] [Revised: 05/12/2024] [Accepted: 06/05/2024] [Indexed: 06/24/2024]
Abstract
Approximately 5-15% of all dermatologic malignancies manifest in the upper and lower eyelids. The primary types include basal cell carcinoma, squamous cell carcinoma, and sebaceous cell carcinoma, with Merkel cell carcinoma and melanoma following closely behind. Basal cell carcinoma predominantly affects the lower eyelid, yet various other carcinomas, melanomas, metastases, and neoplasms of diverse origins can arise on both upper and lower eyelids. Risk factors such as advanced age, smoking, and notably, exposure to UV light significantly contribute to the development of these eyelid lesions. Despite the increasing incidence, research on dermatologic eyelid malignancies remains limited. However, such study is imperative given that many systemic oncologic malignancies initially present as metastatic eyelid lesions. This paper provides an in-depth exploration of eyelid anatomy, clinical presentation, diagnosis, and treatment management.Key Points: Eyelid metastases represent less than one percent of all eyelid cancers, yet they often serve as the initial indication of an underlying systemic malignancy. Early detection and treatment is crucial in improving prognosis and quality of life for patients. Treatment options encompass a range of modalities, with Mohs surgery as the gold standard for the removal of ocular tumors. Additional treatment options include local excision as well as non-surgical interventions such as radiotherapy, cryotherapy, immunotherapy, and topical medications.
Collapse
MESH Headings
- Humans
- Eyelid Neoplasms/therapy
- Eyelid Neoplasms/diagnosis
- Eyelid Neoplasms/epidemiology
- Eyelid Neoplasms/pathology
- Eyelids/pathology
- Mohs Surgery
- Skin Neoplasms/therapy
- Skin Neoplasms/diagnosis
- Skin Neoplasms/pathology
- Skin Neoplasms/epidemiology
- Melanoma/therapy
- Melanoma/diagnosis
- Melanoma/pathology
- Melanoma/epidemiology
- Carcinoma, Merkel Cell/therapy
- Carcinoma, Merkel Cell/diagnosis
- Carcinoma, Merkel Cell/epidemiology
- Carcinoma, Merkel Cell/secondary
- Carcinoma, Merkel Cell/pathology
- Risk Factors
- Carcinoma, Basal Cell/therapy
- Carcinoma, Basal Cell/diagnosis
- Carcinoma, Basal Cell/epidemiology
- Carcinoma, Basal Cell/pathology
- Carcinoma, Basal Cell/secondary
- Quality of Life
- Carcinoma, Squamous Cell/therapy
- Carcinoma, Squamous Cell/diagnosis
- Carcinoma, Squamous Cell/secondary
- Carcinoma, Squamous Cell/pathology
- Carcinoma, Squamous Cell/epidemiology
- Sebaceous Gland Neoplasms/therapy
- Sebaceous Gland Neoplasms/diagnosis
- Sebaceous Gland Neoplasms/pathology
Collapse
Affiliation(s)
- M Mukarram
- Arizona College of Osteopathic Medicine, Midwestern University Glendale, Arizona, USA
| | - A Khachemoune
- Department of Dermatology, University of New York Downstate and Veterans Affairs Medical Center, 800 Poly Pl, Brooklyn, NY, 11209, USA.
| |
Collapse
|
4
|
Chebib E, Rougier G, Dubray-Vautrin A, Martin J, Ghanem W, Lesnik M, Sabran B, Matet A, Malaise D, Cassoux N, Dendale R, Choussy O, Badois N. Lymph Node Evolution in Eyelid and Orbit Squamous Cell Carcinomas. Laryngoscope 2024. [PMID: 39031611 DOI: 10.1002/lary.31584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2024] [Revised: 04/04/2024] [Accepted: 05/22/2024] [Indexed: 07/22/2024]
Abstract
OBJECTIVES To describe a large cohort of eyelid and periorbital SCCs, to compare the location of the tumor and of the pathological lymph nodes, and to analyze the risk factors for lymph node involvement among tumor characteristics. METHODS All patients managed inside our institution for an eyelid and periorbital SCCs were included. Tumor characteristics, imaging setup, excision margins, lymph node evolution features, local, regional, and distant recurrences rates, and global survival were reported. The risk for lymph node involvement and location of pathological lymph nodes were analyzed through univariate and multivariate analyses. RESULTS Between January 2012 and August 2022, 115 patients were included, and 18 presented a lymph node evolution (15.7%), involving the parotid gland in 16 cases (88.9%), the submental and submandibular areas in seven cases (38%), and the jugular and carotid areas in four cases (22%). Tumor size above 20 mm, infiltration of the external canthus and periorbital structures, the presence of perineural invasion or vascular embolism, the depth of infiltration, and the presence of a local recurrence were significantly associated with the risk of lymph node evolution. CONCLUSION Periorbital and eyelid SCCs present a true potential for lymph node evolution especially through the parotid gland. Extension setup including the parotid gland and neck should be mandatory, and lymph node dissection should be associated in case of parotidectomy for lymph node involvement. LEVEL OF EVIDENCE IV Laryngoscope, 2024.
Collapse
Affiliation(s)
- Emilien Chebib
- Head & Neck Oncologic and Reconstructive Surgery Department, Institut Curie, Ear, Nose & Throat, Paris, France
| | - Guillaume Rougier
- Head & Neck Oncologic and Reconstructive Surgery Department, Institut Curie, Ear, Nose & Throat, Paris, France
| | - Antoine Dubray-Vautrin
- Head & Neck Oncologic and Reconstructive Surgery Department, Institut Curie, Ear, Nose & Throat, Paris, France
| | - Joey Martin
- Head & Neck Oncologic and Reconstructive Surgery Department, Institut Curie, Ear, Nose & Throat, Paris, France
| | - Wahib Ghanem
- Head & Neck Oncologic and Reconstructive Surgery Department, Institut Curie, Ear, Nose & Throat, Paris, France
| | - Maria Lesnik
- Head & Neck Oncologic and Reconstructive Surgery Department, Institut Curie, Ear, Nose & Throat, Paris, France
| | - Baptiste Sabran
- Head & Neck Oncologic and Reconstructive Surgery Department, Institut Curie, Ear, Nose & Throat, Paris, France
| | - Alexandre Matet
- Ophthalmology and Ocular Oncology Department, Institut Curie, Paris, France
- Université Paris Cité, Paris, France
| | - Denis Malaise
- Ophthalmology and Ocular Oncology Department, Institut Curie, Paris, France
| | - Nathalie Cassoux
- Ophthalmology and Ocular Oncology Department, Institut Curie, Paris, France
- Université Paris Cité, Paris, France
| | - Rémi Dendale
- Radiation Oncology Department, Institut Curie, Paris, France
| | - Olivier Choussy
- Head & Neck Oncologic and Reconstructive Surgery Department, Institut Curie, Ear, Nose & Throat, Paris, France
| | - Nathalie Badois
- Head & Neck Oncologic and Reconstructive Surgery Department, Institut Curie, Ear, Nose & Throat, Paris, France
| |
Collapse
|
5
|
Patro KC, Avinash A, Banidutta A, Kundu CR, Bhattacharya PS, Pilaka VKR, Muvvala M, Kumar AA, Aketi S, Karthikeyan K, Madasu BK, Vincent DT. Implementing high-dose rate surface mould brachytherapy for carcinoma of eyelid: a practical approach and weekly review. Radiat Oncol J 2024; 42:154-159. [PMID: 38946078 PMCID: PMC11215503 DOI: 10.3857/roj.2023.00682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2023] [Revised: 12/08/2023] [Accepted: 12/08/2023] [Indexed: 07/02/2024] Open
Abstract
Surface mould brachytherapy is a conformal radiotherapy technique that can deliver high dose to the target while sparing nearby normal structures, Here, we aim to describe the procedurals details for high-dose rate (HDR) surface mould brachytherapy in sebaceous carcinoma of eyelid in a 54-year old lady. She was hesitant for surgery and any form of invasive intervention like interstitial brachytherapy. So, she was treated with surface mould HDR brachytherapy to a total dose of 52 Gy in 13 fractions at a dose of 4 Gy per fraction delivered twice daily using Iridium-192 isotope with no acute side effects. She was evaluated on a weekly basis for any radiation side effects and now she is disease-free for 6 months post-treatment with only mild dry eye. A detailed step-by-step procedure of surface mould technique, simulation procedure, dose prescription, planning, plan evaluation and treatment has been described in this paper. Surface mould HDR brachytherapy can be safely used as organ preserving modality of treatment for eyelid carcinoma.
Collapse
Affiliation(s)
- Kanhu Charan Patro
- Department of Radiation Oncology, Mahatma Gandhi Cancer Hospital and Research Institute, Visakhapatnam, Andhra Pradesh, India
| | - Ajitesh Avinash
- Department of Radiation Oncology, SUM Ultimate Medicare, Bhubaneswar, Odisha, India
| | - Arya Banidutta
- Department of Radiation Oncology, Utkal Institute of Medical Sciences, Bhubaneswar, Odisha, India
| | - Chitta Ranjan Kundu
- Department of Radiation Oncology, Mahatma Gandhi Cancer Hospital and Research Institute, Visakhapatnam, Andhra Pradesh, India
| | - Partha Sarathi Bhattacharya
- Department of Radiation Oncology, Mahatma Gandhi Cancer Hospital and Research Institute, Visakhapatnam, Andhra Pradesh, India
| | - Venkata Krishna Reddy Pilaka
- Department of Radiation Oncology, Mahatma Gandhi Cancer Hospital and Research Institute, Visakhapatnam, Andhra Pradesh, India
| | - Mrutyunjayarao Muvvala
- Department of Radiation Oncology, Mahatma Gandhi Cancer Hospital and Research Institute, Visakhapatnam, Andhra Pradesh, India
| | - Ayyalasomayajula Anil Kumar
- Department of Medical Physics, Mahatma Gandhi Cancer Hospital and Research Institute, Visakhapatnam, Andhra Pradesh, India
| | - Srinu Aketi
- Department of Medical Physics, Mahatma Gandhi Cancer Hospital and Research Institute, Visakhapatnam, Andhra Pradesh, India
| | - Keerthiga Karthikeyan
- Department of Radiation Oncology, Mahatma Gandhi Cancer Hospital and Research Institute, Visakhapatnam, Andhra Pradesh, India
| | - Bhargava Krishna Madasu
- Department of Radiation Oncology, Mahatma Gandhi Cancer Hospital and Research Institute, Visakhapatnam, Andhra Pradesh, India
| | - Dona Treesa Vincent
- Department of Radiation Oncology, Mahatma Gandhi Cancer Hospital and Research Institute, Visakhapatnam, Andhra Pradesh, India
| |
Collapse
|
6
|
Bao XL, Sun YJ, Zhan X, Li GY. Orbital and eyelid diseases: The next breakthrough in artificial intelligence? Front Cell Dev Biol 2022; 10:1069248. [PMID: 36467418 PMCID: PMC9716028 DOI: 10.3389/fcell.2022.1069248] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Accepted: 11/08/2022] [Indexed: 12/07/2023] Open
Abstract
Orbital and eyelid disorders affect normal visual functions and facial appearance, and precise oculoplastic and reconstructive surgeries are crucial. Artificial intelligence (AI) network models exhibit a remarkable ability to analyze large sets of medical images to locate lesions. Currently, AI-based technology can automatically diagnose and grade orbital and eyelid diseases, such as thyroid-associated ophthalmopathy (TAO), as well as measure eyelid morphological parameters based on external ocular photographs to assist surgical strategies. The various types of imaging data for orbital and eyelid diseases provide a large amount of training data for network models, which might be the next breakthrough in AI-related research. This paper retrospectively summarizes different imaging data aspects addressed in AI-related research on orbital and eyelid diseases, and discusses the advantages and limitations of this research field.
Collapse
Affiliation(s)
- Xiao-Li Bao
- Department of Ophthalmology, Second Hospital of Jilin University, Changchun, China
| | - Ying-Jian Sun
- Department of Ophthalmology, Second Hospital of Jilin University, Changchun, China
| | - Xi Zhan
- Department of Engineering, The Army Engineering University of PLA, Nanjing, China
| | - Guang-Yu Li
- The Eye Hospital, School of Ophthalmology & Optometry, Wenzhou Medical University, Wenzhou, China
| |
Collapse
|
7
|
Mercut R, Mercut I, Glodeanu A, Ionescu M, Turcu A, Stefanescu‑Dima A, Ciurea M. Eyelid carcinomas: Tumor aggressiveness tendencies for smokers compared to non‑smokers. Exp Ther Med 2022; 23:234. [PMID: 35222711 PMCID: PMC8815059 DOI: 10.3892/etm.2022.11159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Accepted: 09/29/2021] [Indexed: 11/12/2022] Open
Abstract
During the past few years, several studies have demonstrated that head and neck carcinomas present more aggressive forms for smokers, relative to non-smokers. Our aim was to investigate the tumor aggressiveness for patients with eyelid carcinomas, in relation to tobacco consumption, as well as other demographic and clinical data. For 98 patients with eyelid carcinomas, we studied the relationship between the duration of their symptoms and their tumor stage at first diagnosis, trying to determine potential correlations with smoking status and several other clinical parameters. Our data revealed that, for the same duration of symptoms, tobacco consumers tended to have higher tumor stages, which did not correlate with other variables. For early diagnosed tumors, within the first year of symptoms, smokers presented 6.044 times higher odds to exhibit more advanced tumor stages, compared to non-smokers, and this value decreased to 4.501, up to 5 years of the presence of symptoms (P<0.05). We also noted that, for smokers, an increased age was associated with increased tumor stages, which was opposed to non-smokers, regardless of their symptom duration [average odds ratio (OR) 1.122, P<0.05]. Tumor aggressiveness was therefore associated with tobacco consumption, leading to an increased risk of developing more aggressive forms of eyelid carcinomas for smokers, compared to non-smokers.
Collapse
Affiliation(s)
- Razvan Mercut
- Department of Plastic Surgery and Reconstructive Microsurgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
| | - Irina Mercut
- Department of Ophthalmology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
| | - Adina Glodeanu
- Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
| | - Mihaela Ionescu
- Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
| | - Adina Turcu
- Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
| | - Alin Stefanescu‑Dima
- Department of Ophthalmology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
| | - Marius Ciurea
- Department of Plastic Surgery and Reconstructive Microsurgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
| |
Collapse
|
8
|
Stukov AN, Kharitonova NN, Kulikov AN, Vershinina SF, Murazov YG, Zmitrichenko YG, Senchik KY, Tochilnikov GV, Ermakova ED, Filatova LV, Latipova DK, Semiglazova TY. [Activity of the Russian antitumor compound chlonisol in models of eyelid tumors (experimental study)]. Vestn Oftalmol 2022; 138:6-14. [PMID: 36004585 DOI: 10.17116/oftalma20221380416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
UNLABELLED Eyelid tumors are the most common neoplasms in everyday ophthalmic practice and cover a wide range of benign and malignant lesions. Surgical methods, cryodestruction, laser therapy and radiation therapy are used in the treatment of malignant eyelid tumors. Chemotherapy does not occupy a prominent place in the treatment of malignant eyelid tumors, its use is limited to sensitive tumors. OBJECTIVE To assess the antitumor activity of the Russian-developed chemical compound 2-[3-(2-chloroethyl)-3-nitrosoureido]-1.3-propandiol (chlonisol) on the models of transplantable tumors of various histogenesis implanted into the lower eyelid. MATERIAL AND METHODS The study was carried out on 67 mice of lines 129/SN, BALB/c and C57BL/6 that had Ehrlich carcinoma, sarcoma 37, lymphosarcoma LIO-1 and B16 melanoma transplanted into the eyelid. Tumor transplantation was done by injecting 0.05 ml of sterile sodium chloride solution containing 106 cells of Ehrlich carcinoma, sarcoma 37, lymphosarcoma LIO-1, or 10% suspension of tumor tissue of B16 melanoma. The injection was performed into the right lower eyelid in the direction from the outer towards the inner corner of the eye using a thin needle (29G). Chlonisol was administered at the maximum tolerated dose of 20 mg/kg or at the lower dose of 15 mg/kg intraperitoneally 24 hours after tumor transplantation. RESULTS In mice with Ehrlich carcinoma, sarcoma 37, lymphosarcoma LIO-1 and melanoma B16 transplanted under the skin of the lower eyelid, a single intraperitoneal injection of chlonisol at the dose of 20 or 15 mg/kg caused significant inhibition of tumor growth reaching 100%. Chlonisol significantly increased overall survival in animals with Ehrlich carcinoma (log rank test, p=0.0464), sarcoma 37 (log rank test, p<0.0001), lymphosarcoma LIO-1 (log rank test, p=0.0122) and B16 melanoma (log rank test, p<0.0001); the proportion of animals that were fully healed was 25, 78, 67 and 25%, respectively. CONCLUSION Chlonisol has a pronounced antitumor effect in mice with Ehrlich carcinoma, sarcoma 37, lymphosarcoma LIO-1 and B16 melanoma transplanted into the eyelid.
Collapse
Affiliation(s)
- A N Stukov
- N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
| | - N N Kharitonova
- Military Medical Academy named after S.M. Kirov, Saint Petersburg, Russia
| | - A N Kulikov
- Military Medical Academy named after S.M. Kirov, Saint Petersburg, Russia
| | - S F Vershinina
- A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Saint Petersburg, Russia
| | - Ya G Murazov
- N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
| | - Yu G Zmitrichenko
- N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
| | - K Yu Senchik
- N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
| | - G V Tochilnikov
- N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
| | - E D Ermakova
- N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
| | - L V Filatova
- N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
| | - D Kh Latipova
- N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
| | - T Yu Semiglazova
- N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
| |
Collapse
|
9
|
Analysis of Tumour Related Data and Clinical Features of Eyelid Carcinomas. CURRENT HEALTH SCIENCES JOURNAL 2020; 46:222-229. [PMID: 33304622 PMCID: PMC7716762 DOI: 10.12865/chsj.46.03.02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Figures] [Subscribe] [Scholar Register] [Received: 08/07/2020] [Accepted: 09/18/2020] [Indexed: 11/18/2022]
Abstract
Almost 10% of worldwide skin cancers are located at the eyelid level. In European countries, malign eyelid tumours are mostly represented by basal and squamous cell carcinomas, and usually affect elderly patients. In order to study the clinical features of eyelid tumours, and potential correlations between tumour parameters, we have enrolled a cohort of 98 subjects from a south-western region of Romania. Our study confirmed the majority of results from other European studies, as basal cell carcinoma was the most frequent malign form, being diagnosed for more than 85% of patients with declared prolonged sun exposure; tumours were mostly located on the superior eyelid, especially for males, and may present slow progression rates. We have identified significant correlations only between the tumour stage and symptoms' duration, and also between the tumour stage and smoking habit, for females.
Collapse
|
10
|
Ferreira TA, Pinheiro CF, Saraiva P, Jaarsma-Coes MG, Van Duinen SG, Genders SW, Marinkovic M, Beenakker JWM. MR and CT Imaging of the Normal Eyelid and its Application in Eyelid Tumors. Cancers (Basel) 2020; 12:cancers12030658. [PMID: 32178233 PMCID: PMC7139934 DOI: 10.3390/cancers12030658] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2020] [Revised: 02/15/2020] [Accepted: 02/24/2020] [Indexed: 11/16/2022] Open
Abstract
T-staging of most eyelid malignancies includes the assessment of the integrity of the tarsal plate and orbital septum, which are not clinically accessible. Given the contribution of MRI in the characterization of orbital tumors and establishing their relations to nearby structures, we assessed its value in identifying different eyelid structures in 38 normal eyelids and evaluating tumor extension in three cases of eyelid tumors. As not all patients can receive an MRI, we evaluated those same structures on CT and compared both results. All eyelid structures were identified on MRI and CT, except for the conjunctiva on both techniques and for the tarsal muscles on CT. Histopathology confirmed the MRI findings of orbital septum invasion in one patient, and the MRI findings of intact tarsus and orbital septum in another patient. Histopathology could not confirm or exclude tarsal invasion seen on MRI on two patients. Although imaging the eyelid is challenging, the identification of most eyelid structures is possible with MRI and, to a lesser extent, with CT and can, therefore, have an important contribution to the T-staging of eyelid tumors, which may improve treatment planning and outcome.
Collapse
Affiliation(s)
- Teresa A. Ferreira
- Department of Radiology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; (M.G.J.-C.); (J.-W.M.B.)
- Correspondence:
| | - Carolina F. Pinheiro
- Department of Neuroradiology, Centro Hospitalar e Universitario de Lisboa Central, Rua Jose Antonio Serrano, 1150-199 Lisboa, Portugal;
| | - Paulo Saraiva
- Department of Radiology, Hospital da Luz, Estrada Nacional 10, km 37, 2900-722 Setubal, Portugal;
| | - Myriam G. Jaarsma-Coes
- Department of Radiology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; (M.G.J.-C.); (J.-W.M.B.)
- Department of Ophthalmology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; (S.W.G.); (M.M.)
| | - Sjoerd G. Van Duinen
- Department of Pathology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands;
| | - Stijn W. Genders
- Department of Ophthalmology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; (S.W.G.); (M.M.)
| | - Marina Marinkovic
- Department of Ophthalmology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; (S.W.G.); (M.M.)
| | - Jan-Willem M. Beenakker
- Department of Radiology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; (M.G.J.-C.); (J.-W.M.B.)
- Department of Ophthalmology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; (S.W.G.); (M.M.)
| |
Collapse
|
11
|
Mould-based surface high-dose-rate brachytherapy for eyelid carcinoma. J Contemp Brachytherapy 2019; 11:443-448. [PMID: 31749853 PMCID: PMC6854866 DOI: 10.5114/jcb.2019.88619] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2019] [Accepted: 09/16/2019] [Indexed: 11/17/2022] Open
Abstract
Purpose To evaluate toxicity and clinical outcomes in patients with eyelid tumour treated with contact high-dose-rate brachytherapy (HDR-BT). Material and methods Between April 2010 and August 2017, 10 consecutive patients with tumour of the eyelid underwent contact HDR-BT and custom-made surface mould. Every applicator was manually built using conventional thermoplastic material and standard plastic catheters. The median dose prescribed was 42 Gy (range, 30-48) with a median dose per fraction of 3.5 Gy (range, 2-4.5). The dose was delivered in a median of 12 fractions (range, 10-17) over a median of 16 days. In all cases, an ocular shield was placed to reduce the dose to the eye. Acute and late toxicity was evaluated according to RTOG toxicity criteria. Results We analyzed data of 9 of 10 patients (one patient was excluded because he did not give consent for investigation). The median age was 68 years (range, 31-88). According to the TNM-UICC staging system, 4, 1 and 4 patients were stage IA, IB and IC, respectively. Basal cell and sebaceous gland carcinomas were reported in 5 and 2 patients, respectively; other histological types were non-Hodgkin lymphoma and plasmacytoma. After a median follow-up of 51 months (range, 16-90), there was no evidence of local or distant recurrence. The treatment was very well tolerated. Most commonly acute reactions consisted of low grade (G1-G2) conjunctivitis and skin erythema. Only one patient required a temporary interruption of the treatment due to acute G2 conjunctivitis and G3 lid erythema. Only one G2 late toxicity was reported (corneal ulceration), without resulting in functional impairment or blindness. Conclusions Our results suggest that contact HDR-BT with a customized applicator is safe, effective and offers very good local control and can be considered for the treatment of eyelid tumours.
Collapse
|
12
|
Eyelid sebaceous carcinoma: Validation of the 8th edition of the American Joint Committee on cancer T staging system and the prognostic factors for local recurrence, nodal metastasis, and survival. Eye (Lond) 2019; 33:887-895. [PMID: 31147618 DOI: 10.1038/s41433-019-0454-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Revised: 03/05/2019] [Accepted: 03/05/2019] [Indexed: 11/08/2022] Open
Abstract
PURPOSE To investigate the clinicopathological features and prognostic factors for eyelid sebaceous gland carcinoma (SGC) in an ethnic Chinese population and to validate the performance of the T category of the 8th edition AJCC staging systems, with the aim of providing information for refinements. METHODS Sixty-three patients with pathological diagnosis of SGC were enroled retrospectively. The clinicopathological features, treatments, and outcomes were collected. Prognostic factors associated with the outcome of local recurrence, regional lymph node metastasis, and tumour-related death were analysed. The performance analysis was performed by comparing the predictive value for survival and the monotonicity of gradients between the 7th and 8th staging systems. RESULTS The distribution of T1:T2:T3:T4 tumours according to the 7th and 8th edition was 6:40:16:1 and 23:26:5:9, respectively. Positive surgical margin was a poor prognostic factor. Local recurrence was associated with more aggressive histopathological features and surrounding structure invasions. Regional lymph node metastasis was associated with larger tumours. The T category of 8th edition showed better predictability for local recurrence and regional lymph node metastasis, while the T category of 7th edition had better monotonicity of gradients. Tumours classified as T2c or worse had higher risk of regional lymph node metastasis, while tumours T3b or worse in the 8th edition had more tumour-related death. CONCLUSIONS Patients with higher T category are at risk of regional lymph node metastasis and tumour-related death. Further refinement of the T category of AJCC staging system can focus on the predictability for local recurrence and the monotonicity of gradients.
Collapse
|
13
|
Electrochemotherapy in the treatment of locally advanced or recurrent eyelid-periocular basal cell carcinomas. Sci Rep 2019; 9:4285. [PMID: 30862897 PMCID: PMC6414678 DOI: 10.1038/s41598-019-41026-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Accepted: 02/25/2019] [Indexed: 12/21/2022] Open
Abstract
There is increasing evidence about the effectiveness of electrochemotherapy (ECT) in the treatment of basal cell carcinomas in the head and neck region, although its role in the management of eyelid-periocular skin tumors has to be clarified. The aim of the present study is to evaluate the results of ECT in the treatment of locally advanced primary and recurrent eyelid-periocular skin basal cell carcinomas. Twelve patients with basal cell carcinoma involving the eyelid-periocular skin region were treated with ECT. Three patients had locally advanced primary tumors, while 9 patients had recurrent tumors. All treatments were performed according to the ESOPE guidelines, using Cliniporator TM device. All patients received bleomycin based ECT. The route of administration was intratumoral in 3 patients and intravenous in 9 patients. Tumor response was evaluated using the RECIST 1.1. criteria. ECT resulted in complete response of the periocular skin tumors in all patients. Lower eyelid ectropion was developed in 3 patients which had to be corrected surgically. ECT can be used effectively in the treatment of locally advanced or recurrent basal cell carcinomas in the eyelid-periocular skin region. Excellent tumor control can be achieved with good functional and cosmetic results without systemic adverse events with short interval follow-up.
Collapse
|
14
|
Treatment of squamous cell carcinoma of the eyelid with imiquimod 5% cream. Can J Ophthalmol 2019; 54:e24-e27. [DOI: 10.1016/j.jcjo.2018.03.010] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Revised: 03/20/2018] [Accepted: 03/27/2018] [Indexed: 11/22/2022]
|
15
|
Tas F, Erturk K. Palpebral cutaneous melanomas: a review of 17 cases from a tertiary center. Int J Dermatol 2019; 58:75-79. [PMID: 30171604 DOI: 10.1111/ijd.14212] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/27/2017] [Revised: 05/01/2018] [Accepted: 08/07/2018] [Indexed: 12/01/2022]
Abstract
BACKGROUND Melanomas arising from eyelid skin are exceptionally rare, accounting for <1% of eyelid malignancies and all cutaneous melanomas. The aim of this study was to identify the histopathological features and clinical behaviors of the palpebral skin melanoma patients from a single tertiary institution. PATIENTS AND METHODS Seventeen Caucasian patients diagnosed with eyelid cutaneous melanoma were analyzed retrospectively. RESULTS The median age of patients was 59 years, and females were predominant (n = 11). The most frequent localization of the lesions was the lower eyelid (n = 8). Nodular (n = 4), lentigo maligna (n = 3), and the superficial spreading melanoma (n = 3) were the most common histopathological subtypes. Only three patients had in situ melanomas. Tumor infiltrating lymphocytes were present in most of the patients; however, only a few cases had lymphovascular invasion. Regional lymph node involvement was present in two patients, and distant metastasis was found in only one patient. Four patients (24%) had disease relapses during follow-up, all of which were locoregional. The median relapse-free survival (RFS) time and 5-year RFS rate were 26.3 months and 60.4%, respectively. Two patients (12%) died. Median OS time was 32.1 months, and 5-year OS rate was 84%. Being elderly (older than 60 years of age) (P = 0.05), lesion originating from canthus compared to eyelid (P = 0.03) and presence of recurrence in follow-up (P = 0.04) have been found as poor prognostic indicators for OS. CONCLUSION Palpebral skin melanoma is associated with favorable clinical features, and it is correlated with better survival rates.
Collapse
Affiliation(s)
- Faruk Tas
- Department of Medical Oncology, Institute of Oncology, University of Istanbul, Istanbul, Turkey
| | - Kayhan Erturk
- Department of Medical Oncology, Institute of Oncology, University of Istanbul, Istanbul, Turkey
| |
Collapse
|
16
|
Suzuki S, Yasukawa S, Tsuchimochi R, Inoue T. Gamma knife radiosurgery for basal cell carcinoma of the eyelid: report of a case. Acta Neurochir (Wien) 2018; 160:357-359. [PMID: 29080088 DOI: 10.1007/s00701-017-3370-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2017] [Accepted: 10/17/2017] [Indexed: 12/01/2022]
Abstract
Basal cell carcinoma (BCC) is the most common malignancy in the face. Surgical removal and reconstruction is the first choice of treatment options for BCC, but it tends to be invasive and sometimes is accompanied by a drastic change in appearance. We report here a case of BCC in the eyelid of a patient who was successfully treated by gamma knife radiosurgery (GKRS). He was 88 years old at this time. The ulcer disappeared within 3 weeks after GKRS and was covered with normal epithelium. This is the first report to describe an eyelid BCC that was treated by GKRS.
Collapse
Affiliation(s)
- Satoshi Suzuki
- Department of Neurosurgery, Fukuoka Kieikai Hospital, 5-11-5 Chihaya, Higashi-ku, Fukuoka, 813-0044, Japan.
- Gamma House, Steel Memorial Yawata Hospital, Kitakyushu, Japan.
- Department of Neurosurgery, Steel Memorial Yawata Hospital, Kitakyushu, Japan.
| | - Shinsuke Yasukawa
- Department of Dermatology, Steel Memorial Yawata Hospital, Kitakyushu, Japan
| | - Ryosuke Tsuchimochi
- Department of Neurosurgery, Steel Memorial Yawata Hospital, Kitakyushu, Japan
| | - Takuya Inoue
- Gamma House, Steel Memorial Yawata Hospital, Kitakyushu, Japan
- Department of Neurosurgery, Steel Memorial Yawata Hospital, Kitakyushu, Japan
| |
Collapse
|
17
|
Tchernev G, Lotti T, Lozev I, Maximov GK, Wollina U. Peri - and Intraocular Mutilating Advanced Squamous Cell Carcinoma: "Monsters Inside Your Body"? Open Access Maced J Med Sci 2018; 6:132-133. [PMID: 29484009 PMCID: PMC5816283 DOI: 10.3889/oamjms.2018.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2017] [Revised: 08/22/2017] [Accepted: 08/24/2017] [Indexed: 11/24/2022] Open
Abstract
Periocular malignancies represent between 5% and 10% of all types of skin cancers. The incidence of eyelid (but also the periocular located) malignancies seems to differ in distribution across the continents. The incidence of eyelid tumours (but also the periocular located tumours) in a predominantly white population determined that BCC is the most common malignant periocular eyelid tumour in whites. This finding has been replicated consistently throughout the literature, with BCC representing 85–95% of all eyelid malignancies, SCC representing 3.4 - 12.6%, Seb Ca representing 0.6 - 10.2%, and both melanoma and Merkel cell carcinoma representing less than 1%. Most periocular skin cancers are associated with ultraviolet radiation (UVR) exposure. Ultraviolet radiation causes local immune suppression, which, coupled with DNA abnormalities in tumour suppressor genes and oncogenes, leads to the development of skin cancers. We are presenting a 62 - year - old patient with a small nodule about 2 cm away from the lower lid of his left eye. A tumour was surgically treated. Several years later there was a tumour relapse, treated with radiotherapy and subsequent chemotherapy with Endoxan and Cisplatin. After the second relapse, he was treated surgically in general anaesthesia by orbital exenteration, removal of the orbital floor and resection of zygomatic bone and the maxillary sinus. A couple of months later, he developed a tumour relapse in the scars and the area of a primary tumour with tumour progression. A possible therapy with Cetuximab or radiation therapy was discussed as a possible treatment option.
Collapse
Affiliation(s)
- Georgi Tchernev
- Medical Institute of Ministry of Interior Department of General, Vascular and Abdominal Surgery, Sofia, Bulgaria.,"Onkoderma"- Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria
| | - Torello Lotti
- University G. Marconi of Rome - Dermatology and Venereology, Rome, Italy
| | - Ilia Lozev
- Medical Institute of Ministry of Interior Department of General, Vascular and Abdominal Surgery, Sofia, Bulgaria
| | | | - Uwe Wollina
- Städtisches Klinikum Dresden - Department of Dermatology and Allergology, Dresden, Sachsen, Germany
| |
Collapse
|